Hyung-Geun Moon1, Seung-Jae Kim1, Myoung Kyu Lee1, Homan Kang2, Hak Soo Choi2, Anantha Harijith3, Jinhong Ren4, Viswanathan Natarajan1,5, John W Christman6, Steven J Ackerman5,7, Gye Young Park1. 1. Division of Pulmonary, Critical Care, Sleep and Allergy, Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA. 2. Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. 3. Department of Pediatrics, University of Illinois at Chicago, IL, USA. 4. Center for Biomolecular Science, College of Pharmacy, University of Illinois at Chicago, IL, USA. 5. Department of Pharmacology, University of Illinois at Chicago, IL, USA. 6. Section of Pulmonary, Critical Care, and Sleep Medicine, Davis Heart and Lung, the Ohio State University, Columbus, OH, USA. 7. Department of Biochemistry and Molecular Genetics, and Medicine, University of Illinois at Chicago, IL, USA.
Abstract
BACKGROUND: A new approach targeting aeroallergen sensing in the early events of mucosal immunity could have greater benefit. The CSF1-CSF1R pathway has a critical role in trafficking allergens to regional lymph nodes through activating dendritic cells. Intervention in this pathway could prevent allergen sensitization and subsequent Th2 allergic inflammation. OBJECTIVE: To examine the therapeutic effectiveness of CSF1 and CSF1R inhibition for blocking the dendritic cell function of sensing aeroallergens. METHODS: We adopted a model of chronic asthma induced by a panel of three naturally occurring allergens and novel delivery system of CSF1R inhibitor encapsulated nanoprobe. RESULTS: Selective depletion of CSF1 in airway epithelial cells abolished the production of allergen-reactive IgE, resulting in prevention of new asthma development as well as reversal of established allergic lung inflammation. CDPL-GW nanoprobe containing GW2580, a selective CSF1R inhibitor, showed favorable pharmacokinetics for inhalational treatment and intranasal insufflation delivery of CDPL-GW nanoprobe ameliorated asthma pathologies including allergen-specific serum IgE production, allergic lung and airway inflammation and airway hyper-responsiveness (AHR) with minimal pulmonary adverse reaction. CONCLUSION: The inhibition of the CSF1-CSF1R signaling pathway effectively suppresses sensitization to aeroallergens and consequent allergic lung inflammation in a murine model of chronic asthma. CSF1R inhibition is a promising new target for the treatment of allergic asthma.
BACKGROUND: A new approach targeting aeroallergen sensing in the early events of mucosal immunity could have greater benefit. The CSF1-CSF1R pathway has a critical role in trafficking allergens to regional lymph nodes through activating dendritic cells. Intervention in this pathway could prevent allergen sensitization and subsequent Th2allergic inflammation. OBJECTIVE: To examine the therapeutic effectiveness of CSF1 and CSF1R inhibition for blocking the dendritic cell function of sensing aeroallergens. METHODS: We adopted a model of chronic asthma induced by a panel of three naturally occurring allergens and novel delivery system of CSF1R inhibitor encapsulated nanoprobe. RESULTS: Selective depletion of CSF1 in airway epithelial cells abolished the production of allergen-reactive IgE, resulting in prevention of new asthma development as well as reversal of established allergic lung inflammation. CDPL-GW nanoprobe containing GW2580, a selective CSF1R inhibitor, showed favorable pharmacokinetics for inhalational treatment and intranasal insufflation delivery of CDPL-GW nanoprobe ameliorated asthma pathologies including allergen-specific serum IgE production, allergic lung and airway inflammation and airway hyper-responsiveness (AHR) with minimal pulmonary adverse reaction. CONCLUSION: The inhibition of the CSF1-CSF1R signaling pathway effectively suppresses sensitization to aeroallergens and consequent allergic lung inflammation in a murine model of chronic asthma. CSF1R inhibition is a promising new target for the treatment of allergic asthma.
Authors: Yong Gyu Lee; Jong Jin Jeong; Sharmilee Nyenhuis; Evgeny Berdyshev; Sangwoon Chung; Ravi Ranjan; Manjula Karpurapu; Jing Deng; Feng Qian; Elizabeth A B Kelly; Nizar N Jarjour; Steven J Ackerman; Viswanathan Natarajan; John W Christman; Gye Young Park Journal: Am J Respir Cell Mol Biol Date: 2015-06 Impact factor: 6.914
Authors: Stephen J Teach; Michelle A Gill; Alkis Togias; Christine A Sorkness; Samuel J Arbes; Agustin Calatroni; Jeremy J Wildfire; Peter J Gergen; Robyn T Cohen; Jacqueline A Pongracic; Carolyn M Kercsmar; Gurjit K Khurana Hershey; Rebecca S Gruchalla; Andrew H Liu; Edward M Zoratti; Meyer Kattan; Kristine A Grindle; James E Gern; William W Busse; Stanley J Szefler Journal: J Allergy Clin Immunol Date: 2015-10-27 Impact factor: 10.793
Authors: William W Busse; Wayne J Morgan; Peter J Gergen; Herman E Mitchell; James E Gern; Andrew H Liu; Rebecca S Gruchalla; Meyer Kattan; Stephen J Teach; Jacqueline A Pongracic; James F Chmiel; Suzanne F Steinbach; Agustin Calatroni; Alkis Togias; Katherine M Thompson; Stanley J Szefler; Christine A Sorkness Journal: N Engl J Med Date: 2011-03-17 Impact factor: 91.245
Authors: Joanne E Sordillo; Roxanne Kelly; Supinda Bunyavanich; Michael McGeachie; Weiliang Qiu; Damien C Croteau-Chonka; Manuel Soto-Quiros; Lydiana Avila; Juan C Celedón; John M Brehm; Scott T Weiss; Diane R Gold; Augusto A Litonjua Journal: J Allergy Clin Immunol Date: 2015-04-24 Impact factor: 10.793
Authors: Virginija Danylaité Karrenbauer; Robert A Harris; Jinming Han; Violeta Chitu; E Richard Stanley; Zbigniew K Wszolek Journal: Cell Mol Life Sci Date: 2022-04-02 Impact factor: 9.207